We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Xilio Therapeutics Inc (XLO) USD0.0001

Sell:$0.56 Buy:$0.59 Change: $0.0098 (1.72%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.0098 (1.72%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.0098 (1.72%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company, which is focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The Company has built its geographically precise solutions platform to rapidly engineer molecules, including cytokines and other biologics. Its tumor-activated, clinical-stage product candidates are XTX202, an interleukin 2 (IL-2), therapy, XTX301, an interleukin 12 (IL-12), therapy and XTX101. Its XTX101 is designed to deplete regulatory T cells when activated (unmasked) in the tumor microenvironment and improve upon the therapeutic index of existing anti-CTLA-4 therapies. Its XTX101 in an ongoing Phase I clinical trial in patients with advanced solid tumors. XTX202 is an investigational tumor-activated beta-gamma biased (non-alpha), engineered IL-2 molecule designed to potently stimulate CD8+ effector T cells and NK cells without concomitant stimulation of regulatory T cells.

Contact details

828 Winter Street, Suite 300
United States
+1 (617) 4304680

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$15.18 million
Shares in issue:
27.54 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Rene Russo
    President, Chief Executive Officer, Director
  • Christopher Frankenfield
    Chief Operating Officer
  • Kevin Brennan
    Senior Vice President - Finance & Accounting
  • Scott Coleman
    Chief Development Officer
  • Katarina Luptakova
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.